Octagon Capital Advisors LP Stoke Therapeutics, Inc. Transaction History

Octagon Capital Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.65 - $10.38 $4.42 Million - $6 Million	-577,787 Reduced 75.68%	185,669 $1.55 Million
Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $518,000 - $1.2 Million	-50,000 Reduced 6.15%	763,456 $10.1 Million
Q1 2022 May 16, 2022	BUY	$17.19 - $26.1 $510,319 - $774,830	29,687 Added 3.79%	813,456 $17.1 Million
Q4 2021 Feb 14, 2022	BUY	$18.11 - $30.72 $8.82 Million - $15 Million	486,947 Added 164.05%	783,769 $18.8 Million
Q2 2021 Aug 16, 2021	BUY	$30.53 - $41.09 $9.06 Million - $12.2 Million	296,822 New	296,822 $9.99 Million

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $367M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.